Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Methylprednisolone
Drug ID BADD_D01433
Description Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone].[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957.[L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.[A192813] The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials.[L12666]
Indications and Usage Oral and intramuscular methylprednisolone are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, nervous system, and other disorders.[L10785,L10788] Intra-articular and soft tissue injections are indicated for short term treatment of acute gouty arthritis, acute and subactute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis.[L10788] Intralesional injections are indicated for alopecia areata, discoid lupus erythematosus, keloids, lichen planus, lichen simplex chronicus and psoriatic plaques, necrobiosis lipoidica diabeticorum, and localized hypertrophic infiltrated inflammatory lesions of granuloma annulare.[L10788]
Marketing Status approved; vet_approved
ATC Code D07AA01; D10AA02; H02AB04
DrugBank ID DB00959
KEGG ID D00407
MeSH ID D008775
PubChem ID 6741
TTD Drug ID D08PIQ
NDC Product Code 72647-331; 0781-5022; 80425-0230; 59746-003; 59762-0049; 63187-160; 71205-453; 0603-4593; 82094-402; 60722-1003; 64958-0084; 55289-649; 59762-4440; 63629-2218; 68001-557; 68001-560; 80425-0242; 22552-0029; 0009-0056; 45865-104; 59762-0050; 59762-0051; 60760-373; 63187-802; 65162-871; 68071-5221; 70121-1000; 59746-015; 65162-982; 68001-005; 68071-4028; 68084-149; 68788-4593; 71205-054; 72189-264; 82094-401; 45865-417; 50090-3094; 59746-002; 63629-2433; 68001-558; 68180-686; 69306-400; 70518-3622; 82094-403; 59746-001; 68071-2301; 68180-687; 70518-2982; 70771-1348; 70771-1349; 80425-0255; 0009-0073; 49999-153; 53002-3120; 63629-2226; 68001-559; 68180-685; 68180-688; 68382-917; 68382-918; 68382-919; 70771-1350; 80425-0231; 0904-6914; 49452-4686; 51552-0603; 0009-0020; 42806-400; 65162-984; 68180-689; 68382-916; 68788-8276; 69306-004; 70121-1001; 70771-1351; 76420-041; 82298-118; 76420-193; 82094-404; 82094-405; 51927-0201; 0009-0022; 65162-980; 68071-2745; 68788-7833; 0009-0038; 57582-011; 0009-0176; 57582-101
UNII X4W7ZR7023
Synonyms Methylprednisolone | Metipred | 6-Methylprednisolone | 6 Methylprednisolone | Urbason | Medrol
Chemical Information
Molecular Formula C22H30O5
CAS Registry Number 83-43-2
SMILES CC1CC2C3CCC(C3(CC(C2C4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Substance-induced psychotic disorder12.03.01.053; 19.03.01.0070.000189%Not Available
Language disorder19.19.01.006; 17.02.08.0150.000048%Not Available
Perforation08.01.03.0580.000032%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000160%
Anal incontinence17.05.01.021; 07.01.06.0290.000032%
Mucocutaneous ulceration23.07.03.018--Not Available
Persecutory delusion19.10.01.0070.000032%Not Available
Thyrotoxic periodic paralysis17.01.04.021; 14.11.01.045; 05.02.02.0050.000032%Not Available
Cardiomyopathy acute02.04.01.0080.000032%Not Available
Cubital tunnel syndrome17.09.02.0090.000032%Not Available
Palatal oedema07.05.04.0080.000032%Not Available
Cell death14.11.02.005; 08.03.03.0030.000064%Not Available
Neurogenic shock24.06.02.023; 17.02.10.025--Not Available
Foot deformity15.10.03.0050.000032%Not Available
Scleroderma renal crisis24.08.08.003; 20.01.03.026; 15.06.01.017; 10.04.07.0040.000032%Not Available
Relapsing-remitting multiple sclerosis17.16.01.007--Not Available
Tongue exfoliation07.14.02.0200.000032%Not Available
Rectal fissure07.03.01.0070.000032%
Necrotising retinitis24.04.10.006; 06.04.06.0120.000048%Not Available
Skin plaque23.03.03.0440.000032%Not Available
Distributive shock24.06.02.0220.000032%Not Available
Spinal pain15.02.01.008; 08.01.08.030; 17.10.01.020--Not Available
Diabetic metabolic decompensation14.07.03.003; 05.07.03.0030.000032%Not Available
Disorganised speech19.19.02.005; 17.02.08.0170.000032%Not Available
Behaviour disorder19.01.01.0050.000032%Not Available
Cerebral venous sinus thrombosis24.01.04.021; 17.08.03.0060.000048%Not Available
Coronary artery dilatation24.03.04.012; 02.02.01.0190.000032%Not Available
Drug effective for unapproved indication12.09.02.001; 08.06.01.0370.000080%Not Available
Drug ineffective for unapproved indication12.09.02.002; 08.06.01.0380.000748%Not Available
Dural arteriovenous fistula24.03.03.047; 17.08.02.0320.000080%Not Available
The 21th Page    First    Pre   21 22    Next   Last    Total 22 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene